AbbVie's head of global head of immunology discovery research says the ability to profile patients at the molecular level has the potential to dramatically change treatment for people living with chronic conditions.
New testing means patients no longer 'defined by their symptoms'
February 26, 2019 Latest NewsBioPharmaDispatch Executive
Latest Video
New Stories
-
Experienced innovation leader joins AusBiotech as its Head of Investment
August 13, 2025 - - Australian Biotech -
Government review and action timelines are in 'dog years' compared to AI
August 13, 2025 - - Latest News -
Australia is not alone in tripping over reform of medical device funding frameworks
August 12, 2025 - - Latest News -
Biogen announces leadership transition for Australia and New Zealand
August 12, 2025 - - Latest News -
If the cost of this process is truly rising at this rate, then the process must be the problem
August 12, 2025 - - Latest News -
Pharmac announces plan to update access and supply of COVID-19 treatments
August 12, 2025 - - Latest News -
Syntara receives FDA guidance for amsulostat in myelofibrosis treatment
August 11, 2025 - - Australian Biotech